May 24, 2010 /
May 24th, 2010
article source: MHT
Biogen Idec Inc. will pay $30 million to Abbott Laboratories in conjunction with the launch of a new Phase 3 trial for a drug candidate targeting multiple sclerosis.
The two companies announced today that the first patient enrolled in the study to test the efficacy and safety of a drug target called Daclizumab, compared to Avonex, an approved drug sold by Biogen. The study is expected to enroll 1,500 patients in 28 countries, and the drug will be administered under the skin, once a month.
*********************************
Learn more of MS when registered at:
……………………………………………..
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY
